SEC Filing Summary: BioSig Technologies, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioSig Technologies, Inc. (not Streamex Corp.) on June 10, 2024, covering events occurring on June 5, 2024. The registrant is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM. The filing primarily addresses significant changes in executive leadership regarding financial oversight.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figure disclosed relates to executive compensation:
- Interim CFO Compensation: $15,000 per month fixed rate.
- Expense Reimbursement: Usual and customary business expenses.
Material Changes
The filing reports the following material changes in corporate governance and personnel:
- Resignation: Mr. Frederick D. Hrkac resigned as Acting Chief Financial Officer and Principal Accounting Officer effective June 5, 2024.
- Appointment: Mr. Ferdinand Groenewald was appointed as Interim Chief Financial Officer, Principal Accounting Officer, and Vice President of Finance effective June 5, 2024.
- Agreement Terms: The consulting agreement is indefinite and terminable by either party with 30 days' advance notice.
Outlook, Risks, and Management Commentary
Management Commentary: The company issued a press release on June 10, 2024, confirming the appointment of Mr. Groenewald to lead accounting and financial reporting activities. Mr. Groenewald brings prior experience as CFO and Chief Accounting Officer at Muscle Maker, Inc., and currently serves as VP of Finance at Alaunos Therapeutics, Inc.
Risks and Contingencies: The filing does not disclose new material risks, contingencies, or unusual items beyond the standard transition of financial leadership. The agreement includes customary indemnification terms for the officer.
Investor Verification Checklist
- Verify the effective date of the CFO transition (June 5, 2024) and the status of the previous acting CFO.
- Review the attached press release (Exhibit 99.1) for additional context on the leadership change.
- Confirm the interim nature of the appointment and the 30-day termination clause in the consulting agreement.
- Note that this filing contains no updated financial results; refer to the most recent 10-Q or 10-K for financial performance data.